What's new in 2020:
- Table 1: Osteomyelitis, meningitis, amnionitis, gastric ulcer, traveler’s diarrhea, C. difficile, keratitis, epididymo-orchitis, septic arthritis, prosthetic joint infection, pneumonia (empiric: age-determined, CAP, HAP, VAP; and specific, esp. GNB); secondary peritonitis, pharyngitis, parapharyngeal space infection, ulcerated skin, bacillary angiomatosis, thrombophlebitis
- Table 2: Updated treatment options overview, especially gram-negative bacilli
- Table 3: Duration of therapy: bacteremia, bone, genital, intra-abdominal, kidney
- Table 4: New drugs and updates reflecting shifting susceptibility/resistance patterns
- Table 5: Highly resistant bacteria, especially GNB
- Table 6: MRSA
- Table 7: New desensitization protocols
- Table 8: Pregnancy risk & lactation safety for new drugs
- Table 9: PK & interactions data for new drugs
- Table 10: New antibacterials, including cefidericol, imipenem-cilastatin-relebactam, lefamulin and drug information for agents available in other regions, e.g., IV forsfomycin
- Table 11: Updated recommendations, including Candida auris
- Table 12: Updated recommendations for MDR tuberculosis and non-tuberculous mycobacteria
- Table 13: Updated recommendations and drug availability for intestinal protozoa, malaria, trypanosomiasis, worms
- Table 14: Adenovirus, coronavirus (2019-nCoV), Ebola, Epstein-Barr virus, neonatal herpes, influenza, measles; HIV – new ARVs
- Table 15: Surgical prophylaxis
- Table 16: Updated pediatric dosing for new and older drugs
- Table 17: Renal impairment adjustments for new and some older drugs; updated obesity dosing
- Table 22: Drug-drug interactions updates for new and existing antimicrobials